Riccardo Lobefaro

1.1k total citations
31 papers, 494 citations indexed

About

Riccardo Lobefaro is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Riccardo Lobefaro has authored 31 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Riccardo Lobefaro's work include Cancer Immunotherapy and Biomarkers (10 papers), Inflammatory Biomarkers in Disease Prognosis (6 papers) and Advanced Breast Cancer Therapies (5 papers). Riccardo Lobefaro is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Inflammatory Biomarkers in Disease Prognosis (6 papers) and Advanced Breast Cancer Therapies (5 papers). Riccardo Lobefaro collaborates with scholars based in Italy, United States and France. Riccardo Lobefaro's co-authors include Claudio Vernieri, Filippo de Braud, Francesca Ligorio, Emma Zattarin, Giulia Salvadori, Valter D. Longo, Fabio Iannelli, Federica Zanardi, Giovanni Fucà and Andrea Vingiani and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cell Metabolism.

In The Last Decade

Riccardo Lobefaro

31 papers receiving 486 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Riccardo Lobefaro Italy	11	265	140	131	112	87	31	494
Francesca Ligorio Italy	12	284 1.1×	138 1.0×	163 1.2×	108 1.0×	52 0.6×	32	512
Toshiaki Iwase United States	13	282 1.1×	114 0.8×	92 0.7×	97 0.9×	133 1.5×	35	439
Neil Majithia United States	12	398 1.5×	83 0.6×	159 1.2×	58 0.5×	84 1.0×	19	565
Mona El-Hashimy United States	11	347 1.3×	91 0.7×	279 2.1×	247 2.2×	90 1.0×	19	708
Kotaro Mizuno Japan	10	164 0.6×	102 0.7×	280 2.1×	173 1.5×	48 0.6×	38	548
Silvia Vázquez Spain	10	116 0.4×	182 1.3×	170 1.3×	110 1.0×	87 1.0×	29	483
Shin-ichi Yamashita Japan	15	149 0.6×	100 0.7×	177 1.4×	165 1.5×	41 0.5×	31	553
Andrew Do United States	11	179 0.7×	77 0.6×	143 1.1×	233 2.1×	52 0.6×	21	443
J Cunningham United States	9	92 0.3×	112 0.8×	153 1.2×	113 1.0×	140 1.6×	15	490

Countries citing papers authored by Riccardo Lobefaro

Since Specialization

Citations

This map shows the geographic impact of Riccardo Lobefaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Riccardo Lobefaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Riccardo Lobefaro more than expected).

Fields of papers citing papers by Riccardo Lobefaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Riccardo Lobefaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Riccardo Lobefaro. The network helps show where Riccardo Lobefaro may publish in the future.

Co-authorship network of co-authors of Riccardo Lobefaro

This figure shows the co-authorship network connecting the top 25 collaborators of Riccardo Lobefaro. A scholar is included among the top collaborators of Riccardo Lobefaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Riccardo Lobefaro. Riccardo Lobefaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cresta, Sara, Anna Tessari, Antonella Aiello, et al.. (2024). 114P Effects of chemotherapy on TREG lymphocytes in early breast cancer. ESMO Open. 9. 102339–102339. 1 indexed citations

Massa, Davide, Claudio Vernieri, Lorenzo Nicolè, et al.. (2023). 1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancer. ESMO Open. 8(1). 101225–101225. 2 indexed citations

Zattarin, Emma, Riccardo Lobefaro, Rita Leporati, et al.. (2023). Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities. Critical Reviews in Oncology/Hematology. 190. 104109–104109. 2 indexed citations

Ligorio, Francesca, Giovanni Fucà, Andrea Vingiani, et al.. (2023). 248P Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus/minus metformin: The BREAKFAST trial. Annals of Oncology. 34. S282–S283. 2 indexed citations

Zattarin, Emma, Federico Nichetti, Francesca Ligorio, et al.. (2022). Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin. Frontiers in Oncology. 12. 925551–925551. 10 indexed citations

Lobefaro, Riccardo, Luigi Mariani, Francesca Ligorio, et al.. (2022). Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison. Clinical Breast Cancer. 23(3). e151–e162. 4 indexed citations

Lobefaro, Riccardo, Luca Porcu, Cinzia Brunelli, et al.. (2022). Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors. ESMO Open. 7(2). 100457–100457. 20 indexed citations

Ligorio, Francesca, Giovanni Fucà, Leonardo Provenzano, et al.. (2022). Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. European Journal of Cancer. 172. 300–310. 50 indexed citations

Ligorio, Francesca, Lorenzo Castagnoli, Andrea Vingiani, et al.. (2021). Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. Cancer Letters. 511. 77–87. 31 indexed citations

10.

Salvadori, Giulia, Federica Zanardi, Fabio Iannelli, et al.. (2021). Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. Cell Metabolism. 33(11). 2247–2259.e6. 99 indexed citations

11.

Ligorio, Francesca, Lorenzo Castagnoli, Emma Zattarin, et al.. (2021). Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. Therapeutic Advances in Medical Oncology. 13. 4277418992–4277418992. 8 indexed citations

12.

Prelaj, Arsela, Claudia Proto, Giuseppe Lo Russo, et al.. (2020). 1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program. Annals of Oncology. 31. S882–S882. 5 indexed citations

13.

Lobefaro, Riccardo, Giuseppe Viscardi, Raimondo Di Liello, et al.. (2020). 1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience. Annals of Oncology. 31. S856–S857. 1 indexed citations

14.

Ferrara, Roberto, Giuseppe Lo Russo, Diego Signorelli, et al.. (2020). Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models.. Journal of Clinical Oncology. 38(15_suppl). 9547–9547. 3 indexed citations

15.

Prelaj, Arsela, Claudia Proto, Giuseppe Lo Russo, et al.. (2020). Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. Translational Lung Cancer Research. 9(3). 617–628. 6 indexed citations

16.

Lobefaro, Riccardo, Emma Zattarin, Federico Nichetti, et al.. (2020). Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis. Therapeutic Advances in Medical Oncology. 12. 3863585121–3863585121. 3 indexed citations

17.

Zattarin, Emma, Rita Leporati, Francesca Ligorio, et al.. (2020). Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. Cells. 9(12). 2644–2644. 43 indexed citations

18.

Viscardi, Giuseppe, Davide Di Natale, Morena Fasano, et al.. (2020). Circulating biomarkers in malignant pleural mesothelioma. SHILAP Revista de lepidopterología. 1(6). 434–451. 7 indexed citations

19.

Pietrantonio, Filippo, Riccardo Lobefaro, Maria Antista, et al.. (2019). A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology. 37(15_suppl). 3509–3509. 1 indexed citations

20.

Pagani, Filippo, Giovanni Randon, Vincenzo Guarini, et al.. (2019). The Landscape of Actionable Gene Fusions in Colorectal Cancer. International Journal of Molecular Sciences. 20(21). 5319–5319. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact